GlassScriptPhysician profile
Kevin P Mays
NPI 1598735144
$548,197.05
in general payments reported to CMS, 2019-2025
35 companies · $79K in 2025
The $79K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $26K · 2021: $45K · 2022: $127K · 2023: $120K · 2024: $87K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $205K · Consulting Fee: $26K · Honoraria: $26K · Travel and Lodging: $16K · Food and Beverage: $14K · Education: $14.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $205,034.00 |
| Consulting Fee | $26,088.00 |
| Honoraria | $25,550.00 |
| Travel and Lodging | $16,391.91 |
| Food and Beverage | $13,886.68 |
| Education | $14.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $130,151.99 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $111,929.56 | 2019-2025 | Ingrezza |
| Abbvie INC. | $78,983.90 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $78,569.25 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $46,275.94 | 2019-2024 | Jornay Pm |
| Alkermes, INC. | $46,120.08 | 2021-2025 | Lybalvi, Aristada |
| Allergan, INC. | $16,650.34 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15,944.41 | 2019-2025 | Trintellix |
| Acadia Pharmaceuticals INC | $8,946.36 | 2019-2025 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $8,015.92 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $1,426.99 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $744.23 | 2019-2025 | Rexulti |
| Corium, LLC | $674.05 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $617.13 | 2019-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $545.43 | 2022-2025 | Auvelity, Sunosi |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $464.57 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $462.73 | 2019-2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $277.43 | 2024-2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $200.34 | 2019-2020 | |
| Neos Therapeutics, LP | $165.50 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $154.25 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $154.09 | 2021-2025 | Loreev Xr |
| Tris Pharma INC | $111.90 | 2019-2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $98.61 | 2020-2023 | Belsomra |
| Bausch Health US, LLC | $90.66 | 2020-2025 | Aplenzin, Wellbutrin |
| Eisai INC. | $81.32 | 2020-2022 | |
| Biogen, INC. | $62.24 | 2021-2024 | |
| Idorsia Pharmaceuticals US INC | $56.00 | 2023-2024 | Quviviq |
| Jazz Pharmaceuticals INC. | $54.00 | 2019-2021 | |
| Noven Therapeutics, LLC | $46.06 | 2022-2024 | Xelstrym |
| Shire North American Group INC | $37.16 | 2019 | |
| Arbor Pharmaceuticals, INC. | $34.91 | 2019 | |
| Alfasigma USA, INC. | $27.57 | 2022 | |
| Amgen INC. | $15.82 | 2019 | |
| Sumitomo Pharma America, INC. | $6.31 | 2023 | Latuda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Mays listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.